• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Tag: Assay Development Services

Sialyltransferases: Sugar Makes the Medicine Go Down?

Monday, 26 June 2017 by Bellbrook Labs
Glycan structures decorate a wide variety of cell types—dotting the surface of blood cells, linked to lipid moieties on neurons, and studding the membrane of tumor cells. These carbohydrate structures create a cellular language that is translated by binding partners, eliciting specific downstream effects. And for some cancers, the effects can be devastating.   Consider
Assay Development ServicesLead Discovery ServicesTranscreener AMP/GMP Assay
Read more
  • Published in Emerging Targets
No Comments

BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery

Wednesday, 14 June 2017 by Bellbrook Labs
BellBrook Labs was recently awarded a $288,000 SBIR Phase I grant from the National Institutes of General Medical Sciences (NIGMS) to develop an HTS assay for cyclic GAMP synthase, an enzyme that triggers immune responses to viruses and tumors. The new assay will be used in an effort to screen for cGAS enzyme modulators as
Assay Development Servicesdrug discovery servicesLead Discovery ServicesTranscreener cGAMP cGAS Assay
Read more
  • Published in Emerging Targets, HTS Assays, News
No Comments

Ectonucleotidases: An Outside Chance for Drug Development

Friday, 28 April 2017 by Bellbrook Labs
Sometimes, the most intriguing cellular processes happen outside of the cell. Case in point: purinergic signaling pathways, in which extracellular receptors sense levels of purines in the extracellular milieu. The result? A wide array of effects on neuronal signaling, vascular tone, thrombosis, and immune function. But what controls the level of extracellular purines? Enter ectonucleotidases:
Assay Development Servicesdrug discovery servicesLead Discovery ServicesTranscreener ADP Kinase AssayTranscreener AMP/GMP Assay
Read more
  • Published in Emerging Targets, HTS Assays, Uncategorized
No Comments

New Publication: HTS Method for Measuring Drug Residence Time

Tuesday, 25 April 2017 by Bellbrook Labs
View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
Assay Development Servicesdrug discovery servicesLead Discovery ServicesResidence TimeTranscreener ADP Kinase AssayTranscreener AMP/GMP AssayTranscreener GDP AssayTranscreener UDP Assay
Read more
  • Published in Company, HTS Assays, News
No Comments

Detecting Rho-GEF Activity Using the Transcreener® GDP Assay

Friday, 24 March 2017 by Bellbrook Labs
Rho GTPases act as molecular switches to regulate the cytoskeletal dynamics underlying cell motility.  Rho GEFs (guanine nucleotide exchange factors) positively regulate Rho GTPases by accelerating GDP dissociation and allowing formation of the active GTPase-GTP complex. Active Rho GTPases typically stimulate cell growth and migration, sometimes triggering tumorigenesis or invasion. Selectively disrupting GEF action using
Assay Development Servicesdrug discovery servicesGEF AssayGTPase AssayLead Discovery ServicesTranscreener GDP Assay
Read more
  • Published in Company, HTS Assays, Products
No Comments

BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services

Wednesday, 22 February 2017 by Bellbrook Labs
Madison, WI, February 2017 – In response to an increasing demand for characterization and prioritization of compounds downstream of HTS or virtual screening, BellBrook Labs is expanding its Drug Discovery Services to include Lead Discovery in addition to Assay Development.  BellBrook will use its proprietary Transcreener® HTS assay platform to accelerate clients’ hit-to-lead and SAR
Assay Development Servicesdrug discovery servicesLead Discovery Services
Read more
  • Published in Company, News
No Comments

Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part II

Wednesday, 19 October 2016 by Bellbrook Labs
In Part I of II in this blog series, discussion included the challenges of screening methyltransferases, steps in developing an SAH assay, the experimental assay procedure, assay sensitivity, and reagent stability. Please view the previous post here: Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I. Compatibility with Diverse MT Accepter Substrates As
AptaFluor SAH Methyltransferase AssayAssay Development Servicesdrug discovery servicesepigeneticsLead Discovery Services
Read more
  • Published in Epigenetics, HTS Assays, Products
No Comments

Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I

Friday, 23 September 2016 by Bellbrook Labs
Riboswitches were discovered in 2002 by Ron Breaker at Yale as RNA-based intracellular sensors of vitamin derivatives. During the last decade, riboswitches have been identified that bind a range of small biomolecules including nucleotides, amino acids, and ions. Riboswitches exert regulatory control of transcription, translation, splicing, and RNA stability. BellBrook scientists used a riboswitch that
AptaFluor SAH Methyltransferase AssayAssay Development Servicesdrug discovery servicesepigeneticsLead Discovery Services
Read more
  • Published in Epigenetics, HTS Assays, Products
No Comments

New Case Study: Discovery of GALNT3 Inhibitors Using a Universal Glycosyltransferase Assay and Orthogonal Pooled Screening

Friday, 27 November 2015 by Bellbrook Labs
Glycosyltransferase (GT) enzymes participate in diverse metabolic and regulatory roles by catalyzing the transfer of sugars to protein, lipid and carbohydrate acceptors as well as to other molecules. Within the GT family, there are over 20 distinct polypeptide N-acetylgalactosaminyltransferases (GALNTs) that catalyze the initial step of O-glycosylation. GALNT3 overexpression and dysregulation has been directly linked
Assay Development ServicesTranscreener GDP Assay
Read more
  • Published in News, Resources
No Comments

“Simplifying HTS with Orthogonal Pooled Screening” Webinar – Encore Presentation

Monday, 17 August 2015 by Edna.Kunkel
Access to this webinar is now available anytime to suit your schedule! In this webinar, Dr. Mel Reichman, Director of Chemical Genomics Center at the Lankenau Institute for Medical Research (LIMR, Wynnewood, PA) describes the Orthogonal Pooled Screening (OPS™) Platform that he developed to provide a drastically more efficient and less expensive approach for rapidly finding
Assay Development Services
Read more
  • Published in News
No Comments
  • 1
  • 2
  • 3

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP